XL 888

Drug Profile

XL 888

Alternative Names: EXEL-4888; Heat Shock Protein 90 Inhibitor XL888; Hsp90 Inhibitor XL888; XL888

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Emory University; Exelixis; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer; Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease) in USA (PO)
  • 28 Jun 2017 Phase-I clinical trials in Gastrointestinal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03095781)
  • 03 Apr 2017 Emory University, Merck Sharp & Dohme and Exelixis plan a phase I trial for Gastrointestinal cancer (Late-stage disease, Combination therapy, Inoperable/unresectable, Metastatic disease, Second-line therapy or greater) in USA (NCT03095781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top